Abstract
In Japanese healthy CYP2C19 extensive metabolizers, rabeprazole 10 mg shows a faster onset of action and stronger inhibition of acid secretion than does omeprazole 20 mg on the first 3 days of administration. We evaluated gastric ulcer improvement after 1 week's treatment with rabeprazole or omeprazole in relation to CYP2C19 polymorphism. A 6-mm rubber disc was placed temporarily at the side of the ulcer for measurement of the ulcer area. The improvement ratios of ulcer area in homozygous extensive metabolizers (homoEMs), heterozygous extensive metabolizers (heteroEMs) and poor metabolizers (PMs) treated with rabeprazole 10 mg were 60.8, 65.0 and 55.3%, respectively, and these values are not significantly different. Corresponding values with omeprazole 20 mg were 46.3, 61.7 and 63.2%, respectively, and the value of homoEMs was significantly smaller than that of heteroEMs. The improvement ratios with rabeprazole in homoEMs and heteroEMs were significantly greater than that with omeprazole in homoEMs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bamberg K, Nylander S, Helander KG, Lundberg LG, Sachs G, Helander HF (1994) In situ hybridization of mRNA for the gastric H+,K(+)-ATPase in rat oxyntic mucosa. Biochim Biophys Acta 1190:355–359
Karam SM, Yao X, Forte JG (1997) Functional heterogeneity of parietal cells along the pit-gland axis. Am J Physiol 272:G161–G171
Carmosino M, Mazzone A, Laforenza U, Gastaldi G, Svelto M, Valenti G (2005) Altered expression of aquaporin 4 and H+/K+-ATPase in the stomachs of peptide YY(PYY) transgenic mice. Biol Cell 97:735–742
Sachs G (2001) Improving on PPI-based therapy of GORD. Eur J Gastroenterol Hepatol 13(suppl 1):S35–S41
Morii M, Takata H, Fujisaki H, Takeguchi N (1990) The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit H+,K(+)-ATPase is correlated with the rate of acid-activation of the inhibitor. Biochem Pharmacol 39:661–667
Besancon M, Simon A, Sachs G (1997) Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 272:22438–22446
Williams MP, Sercombe J, Hamilton MI, Pounder RE (1998) A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 12:1079–1089
Inamori M, Togawa J, Takahashi K, Yoneda M, Fujisawa N, Iwasaki T, Ozawa Y, Kikuchi T, Muramatsu K, Chiguchi G, Matsumoto S, Kawamura H, Abe Y, Kirikoshi H, Kobayashi N, Sakaguchi T, Takamura T, Nakajima A, Ueno N, Sekihara H (2003) Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy? J Gastroenterol Hepatol 18:1034–1038
Shirai N, Furuta T, Moriyama Y, Okochi H, Kobayashi K, Takashima M, Xiao F, Kosuge K, Nakagawa K, Hanai H, Chiba K, Ohashi K, Ishizaki T (2001) Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 15:1929–1937
Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL (2003) Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther 15:1507–1514
Saitoh T, Fukushima Y, Otsuka H, Hirakawa J, Mori H, Asano T, Ishikawa T, Katsube T, Ogawa K, Ohkawa S (2002) Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment Pharmacol Ther 16:1811–1817
Shimatani T, Inoue M, Kuroiwa T, Xu J, Mieno H, Nakamura M, Tazuma S (2006) Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19. Clin Pharmacol Ther 79:144–152
Ishizaki T, Horai Y (1999) Review article: cytochrome P450 and the metabolism of proton pump inhibitors—emphasis on rabeprazole. Aliment Pharmacol Ther 13(Suppl. 3):27–36
de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594–598
Kubota T, Chiba K, Ishizaki T (1996) Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 60:661–666
Ando T, Kato H, Sugimoto N, Nagao Y, Seto N, Hongo H, Kajikawa H, Isozaki Y, Shimozawa M, Naito Y, Yoshida N, Ishizaki T, Yoshikawa T (2005) A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences. Dig Dis Sci 50:1625–1631
Hu Y-M, Xu J-M, Mei Q, Xu X-H, Xu S-Y (2005) Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects. Acta Pharmacol Sin 26:384–388
Sakai T, Aoyama N, Kita T, Sakaeda T, Nishiguchi K, Nishitora Y, Hohda T, Sirasaka D, Tamura T, Tanigawara Y, Kasuga M, Okumura K (2001) CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res 18:721–727
McColl KEL, Kennerley P (2002) Proton pump inhibitors—differences emerge in hepatic metabolism. Digest Liver Dis 34:461–467
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ando, T., Ishikawa, T., Kokura, S. et al. Endoscopic Analysis of Gastric Ulcer after One Week's Treatment with Omeprazole and Rabeprazole in Relation to CYP2C19 Genotype. Dig Dis Sci 53, 933–937 (2008). https://doi.org/10.1007/s10620-007-9965-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-007-9965-3